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ABSTRACT
The prevalence of enterotoxigenic Bacteroides fragilis (ETBF) was investigated in stool specimens from 73
patients with colorectal cancer and from 59 control patients. Stool specimens were cultured on
Bacteroides Bile Esculin agar and B. fragilis was identified by conventional methods. After DNA
extraction, the enterotoxin gene (bft) was detected by PCR in 38% of the isolates from colorectal cancer
patients, compared with 12% of the isolates from the control group (p 0.009). This is the first study
demonstrating an increased prevalence of ETBF in colorectal cancer patients.
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INTRODUCTION
Bacteroides fragilis is an obligate anaerobe that is
found in the colon flora of healthy humans and
animals, and is the Bacteroides species isolated
most frequently from clinical specimens as an
aetiological agent of endogenous suppurative
infections. The pathogenicity of B. fragilis is rela-
ted to its carbohydrate capsule, outer-membrane
proteins and production of specific enzymes,
including a recently recognised enterotoxin called
fragilysin [1,2]. Fragilysin-producing B. fragilis,
termed enterotoxigenic B. fragilis (ETBF), has been
associated with diarrhoea in humans and young
farm animals [3,4]. A significant correlation has
been found between the presence of ETBF in
patient stool specimens, or the toxin gene in
colonic biopsy specimens, and the presence of
active inflammatory bowel disease [5,6].
Koshy et al. [7] demonstrated that treatment of
human colonic epithelial cells (HT29 ⁄C1) with
B. fragilis toxin (BFT) resulted in time- and
concentration-dependent redistribution of actin
microflaments (F-actin), as well as an increase in
cell volume, without causing cell injury. It was
suggested that these changes in F-actin and cell
volume may lead to an alteration in tight-junction
function in the intestinal epithelium, contributing
to the pathogenesis of diarrhoea in ETBF infec-
tion. Another study from the same centre indica-
ted that the target of fragilysin was the cell surface
protein E-cadherin, which is the principal struc-
tural component of the zonula adherens and is
responsible for cell-to-cell adhesion. Fragilysin,
causing cleavage of the extracellular domain of
E-cadherin, leads to complete degradation of this
protein [8]. Following BFT treatment of HT29 ⁄C1
cells, it was also suggested that loss of membrane-
associated E-cadherin triggered the nuclear
localisation of b-catenin, which in turn, after
binding with T-cell factor-dependent transcrip-
tional activators, induced c-myc transcription
and translation, resulting in persistent cellular
proliferation [9].
Although the effect of enterotoxin has been
demonstrated in patients with diarrhoea and
inflammatory bowel disease, no previous study
has investigated ETBF colonisation in patients
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with colorectal cancer. In order to investigate a
possible association between the production of
toxin and tumour development, the present study
investigated the prevalence of ETBF in stool
samples from patients with colorectal cancer in
comparison with patients with no personal or
familial history or diagnosis of colorectal disease.
MATERIALS AND METHODS
Patients
Stool specimens were collected from 73 consecutive colorectal
cancer patients who were admitted to the Departments of
General Surgery at Marmara University Hospital and Gulhane
Military Medical School Hospital, Istanbul, Turkey. All data
concerning age, gender, stage of the cancer and American
Society of Anaesthesiology score (which reflects the general
health status) were retrieved prospectively. During the same
period, 59 healthy subjects, with no personal or familial history
of colorectal disease, whose age and gender matched those of
the cancer patients, were included in the study as controls. A
recent history of diarrhoea was considered to be an exclusion
criterion for recruitment as a control. Informed consent was
obtained and the Marmara University Ethics Committee
approved the study protocol.
Bacterial strains
The stool samples were inoculated on Bacteroides Bile Esculin
Agar (Becton Dickinson, Sparks, MD, USA) plates. After
incubation at 37C for 2–4 days in an anaerobic jar, several
colonies from each plate were tested for aerotolerance. Strict
anaerobes were chosen for identification by conventional
methods on the basis of colonial and cellular morphologies.
Briefly, isolates were identified presumptively as B. fragilis if
they were catalase-positive, were indole-negative and did not
ferment arabinose, rhamnose, trehalose, salicin and xylan [10].
Identifications were then confirmed using the API-20A system
(bioMe´rieux, Marcy l’Etoile, France).
DNA extraction
B. fragilis colonies were picked from culture plates and
suspended in 500 lL of TES (50 mM Tris, pH 8, 50 mM EDTA,
50 mM NaCl) buffer. In brief, the cells were lysed by adding
10 mg lysozyme ⁄mL and incubating at 37C for 30 min, and
then adding 10 mg proteinase K ⁄mL and incubating at 65C
for 45 min. SDS 20% w ⁄v was added and the solution was
incubated until it became translucent. Following three treat-
ments with phenol–chloroform, the aqueous phase was col-
lected. DNA was recovered by ethanol precipitation and
resuspended in water, essentially as described previously [11].
PCR analysis
The enterotoxin gene was amplified by PCR using forward
primer BF3, 5¢-GAGCCGAAGACGGTGTATGTGATTTGT,
and reverse primer BF4, 5¢-TGCTCAGCGCCCAGTATAT-
GACCTAGT [12]. The expected size of the amplification
product was c. 400 bp. PCR was performed in 50-lL vol-
umes containing 25 lL of 2 · PCR Master Mix (Fermentas,
Burlington, Canada), 22 lL of nuclease-free water, 50 pmol of
each primer and 100 ng of DNA template. PCR conditions
comprised 94C for 1 min, followed by 40 cycles of 45 s at
94C, 45 s at 52C, and 45 s at 72C, followed by 7 min at 72C,
using a modification of the protocol described by Pantosti et al.
[13]. Positive and negative controls were the enterotoxigenic
strain NCTC 11295 and the non-toxigenic strain ATCC 25285.
Amplification products were separated by agarose gel electro-
phoresis, visualised by UV illumination following staining
with ethidium bromide, and identified by comparison with
reference markers.
Statistics
Pearson’s chi-square or Fisher’s exact test were used as appro-
priate; p < 0.05 was considered to be significant. Relative risk
calculation with 95% CI was performed only for 2 · 2 tables.
RESULTS
In total, 73 cancer cases (with a male:female ratio
of 33:40) and 59 age-matched controls (male:
female ratio of 26:33) were included in this
prospective study. The median age of the total
cohort was 63 years (range 24–90 years). All cases
and controls were of the same ethnic origin
(Caucasian). The stages of cancer were as follows:
29 (40%) patients in stage I; 22 (30%) in stage II;
and 22 (30%) in stage III. None of the cases or
controls had a previous history of diarrhoea.
B. fragilis was isolated from the stool specimens
of 56 (77%) cancer patients and from 40 (68%)
healthy controls. Thus, the isolation rate was not
statistically different between the two groups
(p > 0.05). In contrast, the bft gene was detected
among the B. fragilis isolates from 21 (38%) of the
56 cancer patients, compared with five (12%) of
the 40 controls. Thus, the rate of bft gene detection
in the B. fragilis isolates from colorectal cancer
patients was significantly higher than in the
isolates from the controls (relative risk 4.16,
95% CI 1.39–12.43; p 0.009; Table 1). American
Society of Anesthesiology scores and the stage
of the cancer were not significant factors for bft
gene positivity among the cancer cases (Table 2).
DISCUSSION
Analyses of possible relationships between BFT
and colon cancer to date have been performed
using HT29 ⁄C1 cell lines [8,9]. In the present
study, the rate of colonisation with ETBF in
patients with colorectal cancer was compared
with that in subjects with no personal or familial
history or diagnosis of colorectal disease. ETBF
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strains were isolated more frequently from colo-
rectal cancer patients than from the matched
controls (38% and 12%, respectively; p 0.009).
The stage of the cancer and the general health
status of the cancer patients did not correlate with
the isolation of bft-positive B. fragilis. The general
health status of the entire cohort was not com-
pared, since the matched controls were chosen
from healthy subjects and it was predictable that
the health status of the control subjects was
superior to that of the cancer patients. However,
when the American Society of Anesthesiology
scores of the cancer patients were assessed, no
difference was found between ETBF-positive and
-negative cases (Table 2).
ETBF strains are emerging enteric pathogens
associated with diarrhoeal disease in humans and
animals [2–4,14–16]. Recent data have suggested
that ETBF is also associated with recurrence of
inflammatory bowel disease [5,6]. The virulence
of ETBF is related to its production of fragilysin, a
zinc-containing metalloprotease with a molecular
mass of 20 kDa. Fragilysin is encoded by the bft
gene and has tight-junction specific effects, which
result in rounding and swelling of surface epi-
thelial cells of the animal intestine, and in alter-
ations of the morphology of intestinal epithelial
cell lines in vitro. It thus contributes to the
pathogenesis of diarrhoea by stimulating the
secretory response [2,17]. BFT also stimulates
intestinal epithelial cells (HT29, T84 cells and
Caco-2) to secrete interleukin-8 (IL-8), which
initiates the recruitment of polymorphonuclear
leukocytes to the intestinal sub-mucosa, resulting
in an inflammatory response that increases intes-
tinal fluid secretion [18,19]. It has been demon-
strated that IL-8 secretion is induced in intestinal
epithelial cells in a concentration-dependent man-
ner by biologically active BFT, and that induction
of IL-8 mRNA expression occurs rapidly and
ceases 6 h after BFT treatment, whereas IL-8
secretion continues for ‡ 18 h. Transcription of
the IL-8 gene in response to BFT stimulation is
thought to be regulated via the nuclear factor
kappa-B activation pathway [19,20].
In addition to its diarrhoeagenic and inflam-
matory effects, the role of BFT in multifactorial
processes in carcinogenesis has also been studied,
since it cleaves E-cadherin bound intracellularly
to b-catenins. Accumulation of free catenins in the
cytosol can lead to transcription of the oncogene
c-myc; thus, the stability of b-catenins within
the cell is critical, and is provided by certain
tumour suppressors, such as the adenomatous
polyposis coli protein (APC) [21]. The tumour-
suppressing function of APC resides in its capa-
city to properly regulate intracellular b-catenin
levels. In contrast, free b-catenin, after translocat-
ing into the nucleus and complexing with mem-
bers of the T-cell factor ⁄ lymphoid enhancer factor
family, functions as a signalling molecule for
activation of these transcriptional activators. This
results in increased expression of Tcf-target genes,
including c-myc. Mutations either in the APC gene
or in genes encoding b-catenins (providing resist-
ance to binding to APC proteins) induce accumu-
lation of free catenins in the cytoplasm, which
leads to increased transcription of oncogenes in
the nucleus.
Another pool of b-catenins in the cytoplasm
is that linked to the intracellular domain of
E-cadherin. E-cadherin can also be regarded as a
tumour suppressor, since it stabilises the second
pool of intracellular b-catenin. However, it is not
clear whether the consequence of E-cadherin
inactivation is similar to that of APC inactivation
[22,23]. Wu et al. [9] demonstrated that fragilysin,
which causes loss of membrane-associated
E-cadherin, triggered the nuclear localisation of
b-catenin in HT29 ⁄C1 cells within 3 h of toxin
treatment, with subsequent induction of c-myc
transcription and stimulation of cellular prolifer-
ation. On the basis of these results, it was
Table 1. Presence of the bft gene in Bacteroides fragilis
isolates from cancer patients and control groups
Group
(B. fragilis-positive)
bft-positive
isolates n (%)
bft-negative
isolates n (%) RR (95% CI) p
Cancer patients
(n = 56)
21 (37.5) 35 (62.5) 4.16 (1.39–12.43) 0.009
Controls (n = 40) 5 (12.5) 35 (87.5)
RR, relative risk.
Table 2. Presence of the bft gene in Bacteroides fragilis
isolates from cancer patients with respect to disease status
Disease status
bft-positive
isolates n (%)
bft-negative
isolates n (%) p
Stage of cancer
I 7 (32) 15 (68)
II 7 (41) 10 (59) 0.65
II 7 (41) 10 (59)
ASA
I 6 (32) 13 (68)
II 9 (47) 10 (53) 0.87
III 6 (33) 12 (67)
ASA, American Society of Anaesthesiology score.
784 Clinical Microbiology and Infection, Volume 12 Number 8, August 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 782–786
concluded that fragilysin is the first known
bacterial toxin to activate Tcf-dependent b-catenin
nuclear signalling in intestinal epithelial cells, and
it was suggested that B. fragilis may have the
potential to contribute to oncogenic transforma-
tion in the colon. The statistically significant rate
of ETBF colonisation in colorectal cancer patients
observed in the present study is in agreement
with this suggestion.
There were several limitations to the present
study. First, the size of the cohort was small.
Second, data concerning several environmental
factors of potential relevance were not collected
from the patients included in this study. Since
carcinogenesis is multifactorial, factors such as
diet, habits and environmental exposure may
have roles in the process. To go beyond the
present tentative conclusion, all possible causat-
ive factors would have to be taken into consid-
eration. Third, the development of colorectal
cancer is a lengthy process. Clarifying the possible
role of microorganisms such as B. fragilis during
pathogenesis therefore requires an observational,
longitudinal population-based study. Clearly, this
was not the design of the study presented here,
and additional investigations are required to
substantiate the present findings that indicate a
possible correlation between the presence of the
bft gene and colon cancer, as well as the sugges-
tion that ETBF may have a role in carcinogenesis.
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